The global protein expression market size was estimated to be US$ 3.2 billion in 2021 and is expected grow at a CAGR of 10.5% between 2023 to 2032.
The information for protein synthesis is encoded in DNA, which is subsequently decoded by strictly controlled regulatory processes to produce messenger RNA (mRNA). Transcription is the act of transferring information from DNA to mRNA, whereas translation is the process of producing protein depending on the sequence dictated by those mRNA molecules. Only after the mRNA sequence is translated in the ribosomes, a polypeptide is created which can then be converted to a functional protein by post-translational modifications in the cytosol.
Uses of protein expression technologies in biomedical field:
Several biotech companies now rely heavily on protein expression to generate new treatments with minimal adverse effects. In addition to the biological synthesis of protein, we can now undertake recombinant protein expressions artificially using methods such as protein chemical synthesis, in-vivo protein expression, and in-vitro protein expression.
Large-scale protein expression systems, also known as production systems, are used in biotechnology, medicine, and life sciences. Reverse transcriptase is used for RNA processing, DNA polymerase is used for PCR, and restriction endonucleases are used for cloning. These reagents are also employed together to create proteins that are used in drug research as biological targets or as prospective medicines. The progress of genetic engineering and recombinant technologies has created numerous options for the synthesis and isolation of recombinant proteins for scientific, medicinal, and industrial applications. Massive recombinant protein synthesis (or expression) and purification are now possible thanks to significant advances in biotechnology.
Factors influencing the growth of protein expression market:
Biologics have proved critical in the treatment of a wide range of medical problems. The popularity of Humira, a rheumatoid arthritis treatment, has motivated many pharmaceutical firms to continue the research and development of biological products. The expanding demand for biologicals raises the likelihood of using protein expression systems in their production. Simultaneous bioprocessing has also emerged as a cutting-edge technology for the manufacture of protein therapeutics as well as the development of upstream and downstream operations. The protein expression marketplace is currently very lucrative as a consequence of the increasing use of biotechnology and genetic engineering in the pharmaceutical industry and within the medical industry.
The pandemic also had a positive impact on the protein expression industry. An accurate understanding of the role of several proteins in the SARS-CoV-2 infection cycle and the progression of COVID-19 had sped up the development of prophylactic and therapeutic interventions. The vast expanse of proteomics provided all of the required tools to assist with this challenge. Researchers showed that developments in proteome technology will not just accelerate work in preventing the coronavirus pandemic, but would also be useful in resolving other challenges.
Growth forecast for different types of protein expression systems:
The prokaryotic protein expression sector held the highest proportion of more than forty percent because it is significantly easier to use and fulfil important research objectives. The segment is expected to hold its position during the projection period due to advantageous characteristics like large-scale heterologous protein manufacturing in a short period of time and at a lower budget.
During the forecast period, the mammalian cell category is also expected to develop at a faster rate. Several pharmaceutical companies have started using mammalian expression systems to generate and manufacture proteins in a transient way or stable cell lines. However, the use of these systems is determined by the objective and strategy may change as per requirement. For example, microbiological expression is appropriate for antigen synthesis, structural research, and activity studies where post-translational is not required. Vaccines and therapeutics businesses, on the other hand, favour mammalian cells for manufacturing due to complex post-translational modification processes. Therefore, an increased process requirement for mammalian expression systems will further boost this market in near future.
Cell-free protein expression is currently being employed due to increased demand and customer acceptance. In-vitro cell-free protein expression is performed without the need for live cells. This approach has a variety of advantages over other protein expression methods, and as a result, it is being widely used. Cell-free expression is becoming more popular due to the advantages of cell-free protein methods, such as increased speed, the ability to express dangerous proteins, and the flexibility of amino acids without selective labelling, among other things. As a result, the unique technology has the potential to accelerate the growth of the cell-free expression sector, which is predicted to enhance the protein expression market.
Hurdles in growth of protein expression market:
The protein expression process will produce crude proteins, which are then isolated and refined. Protein expression and purification are frequently difficult due to the inherent complexity of proteins. Certain sequences or structural elements inside a protein may have an influence on the yield and stability of the recombinant proteins if they are not extracted or purified adequately. Overexpression or accumulation of the target protein may also result in unanticipated physiological changes, such as misfolded proteins or protein breakdown. These concerns impede the adoption of protein therapeutic products, thus slowing the growth of the protein expression market.
Protein expression tools and reagents are expensive due to their high quality and purity. As a result of such high costs, the entire production cost of bioactive proteins rises dramatically. Although E. coli-based protein expression methods are not expensive, large-scale production can be costly. Such high prices of protein expression platforms and reagents in commercial and scientific applications, particularly in developing nations, might be prohibitive and cause decreased adoption of novel treatments.
Regional developments and key companies:
Our protein expression market report examines the regions of North America, Europe, Asia Pacific, the Middle East, and South America. The North American market now has the highest share of the revenue in the protein expression sector. This significant market share can be attributable to the presence of significant competitors in the field, increased R&D investment, and strong biosimilar portfolios. Cooperation between companies and academic institutions has been identified as one of the most effective steps for development that is employed in this region.
Because of the rising approvals of protein therapeutics in numerous treatments, particularly in India and China, Asia Pacific is expected to be the fastest-growing market for protein expression products over the forecast period. Furthermore, the growing emphasis on proteomics and genomics research, as well as increased attempts by institutions for innovative protein therapy development, have provided lucrative positive opportunities for the Asia Pacific market all through the projection period.
This protein expression market research report analyses some of the main stakeholders across the globe Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck Group, New England BioLabs, Inc., Oxford Expression Technologies Ltd., Promega Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Takara Bio, Inc. (Takara Holdings Inc.), and LGC Biosearch Technologies are among the key companies highlighted in the report.
Market Segmentation:
By Expression System
By Application
By End-user
By Geography
Development of new protein treatments for severe diseases, increasing awareness of such treatments and rapid governmental approvals will enable the growth of global protein expression market.
High expenditure for protein synthesis, complex purification strategies and their influence on the yield and stability of the recombinant proteins are some of the problems associated with protein-based treatments which can cause hinderance to the growth of protein expression market.
The protein expression market size was estimated to be US$ 3.2 billion in 2021
The global protein expression market is estimated to expand at a CAGR of 10.5% between 2023 to 2032.
The rising approvals of protein therapeutics in numerous treatments, particularly in India and China, Asia Pacific is expected to be the fastest-growing market for protein expression products over the forecast period.
Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck Group, New England BioLabs, Inc., Oxford Expression Technologies Ltd., Promega Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Takara Bio, Inc. (Takara Holdings Inc.), and LGC Biosearch Technologies are among the key companies in the Global Protein Expression Market.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved